钠-葡萄糖协同转运蛋白2抑制剂对肿瘤影响的研究进展

Research progress on effect of sodium-glucose cotransporter 2 inhibitors on tumor

钠–葡萄糖协同转运蛋白2(SGLT2)抑制剂是近年来上市的一种新型降糖药物,主要通过抑制表达于肾脏近曲小管处的SGLT2来阻止肾脏对葡萄糖的重吸收,从而通过排出糖尿来降低血糖。除降糖作用外,SGLT2抑制剂同时有心血管保护、抑制炎症和氧化应激、改善肾脏疾病预后等多种作用。研究发现SGLT2在多种类型的肿瘤中表达,并可能参与癌细胞对葡萄糖的摄取和利用,抑制这种转运蛋白可以抑制肿瘤的生长。SGLT2被推测有可能成为特定癌症的一种新的肿瘤标志物,而SGLT2抑制剂有望成为一种新的靶向调节葡萄糖摄取的抗肿瘤药物。因此对目前研究关注最多的SGLT2抑制剂对肝癌、乳腺癌、宫颈癌、肺癌、结直肠癌、肾细胞癌、膀胱癌的影响进行了综述。

Sodium glucose cotransporter 2(SGLT2)inhibitor is a novel hypoglycemic drug marketed in recent years.It mainly inhibits the reabsorption of glucose by the kidney by inhibiting the expression of SGLT2 in the proximal convoluting tubule of the kidney,thus reducing blood glucose by excreting sugar and urine.Studies have shown that in addition to the hypoglycemic effect,such drugs as well as cardiovascular protection,inhibiting inflammation and oxidative stress,improving the prognosis of kidney disease and other effects,and the study found that SGLT2 expressed in various types of cancer,and may participate in the cancer cells to glucose uptake and utilization of inhibiting the transporters can inhibit tumor growth.Therefore,SGLT2 is speculated to be a new tumor marker for specific cancers,and SGLT2 inhibitors are expected to become new anti-tumor drugs targeting glucose uptake regulation.This article reviews the research on the effect of SGLT2 inhibitors on liver cancer,breast cancer,cervical cancer,lung cancer,colorectal cancer,renal cell cancer,and bladder cancer.